Outlook Therapeutics priced an underwritten public offering of 55,555,556 shares of common stock and matching warrants at a combined price of $0.99 per unit, for expected gross proceeds of about $55.0 million and estimated net proceeds of about $51.1 million, excluding any exercise of the underwriters' option or the warrants. The company said the financing, together with existing cash, will support the commercial launch of LYTENAVA in the United States, working capital and general corporate purposes. Outlook is targeting a U.S. launch of the FDA-approved wet age-related macular degeneration therapy before the end of 2026 and said current estimates suggest annual U.S. sales could exceed $500 million by 2030. For the third quarter of fiscal 2026 ended June 30, the company reported a net loss attributable to common stockholders of $20.3 million, or $0.15 per share, and cash and cash equivalents of $11.2 million at quarter end, excluding the offering proceeds.